* Hyal Pharmaceutical Corp., of Mississauga, Ontario, said the FDA accepted for review the company's new drug application for Solarase, a topical gel for the treatment of actinic keratosis. Hyal also singed a letter of intent with Fujisawa Healthcare Inc., of Deerfield, Ill., relating to exclusive rights to license Solarase for the U.S., Canada and Mexico.

* OrthoLogic Corp., of Tempe, Ariz., submitted to the FDA an amendment to the company's pre-market approval supplement for the SpinaLogic-1000, which uses OrthoLogic's Combined Magnetic Field technology and is intended to function as an adjunct to spinal fusion surgery to increase the rate of fusion. The amendment provides new analyses of the clinical data plus a proposed change to the indication statement.

No Comments